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Abstract
Background Obesity is a chronic relapsing-remitting disease and a global pandemic, being associated with multiple comorbid-
ities. Laparoscopic adjustable gastric banding (LAGB) is one of the safest surgical procedures used for the treatment of obesity,
and even though its popularity has been decreasing over time, it still remains an option for a certain group of patients, producing
considerable weight loss and improvement in obesity-associated comorbidities.
Methods The aim of this study was to evaluate the impact of weight loss following LAGB on obesity-associated comorbidities,
and to identify factors that could predict better response to surgery, and patient sub-groups exhibiting greatest benefit. A total of
99 severely obese patients (81.2% women, mean age 44.19 ± 10.94 years, mean body mass index (BMI) 51.84 ± 8.77 kg/m2)
underwent LAGB in a single institution. Results obtained 1, 2, and 5 years postoperatively were compared with the pre-operative
values using SPPS software version 20.
Results A significant drop in BMI was recorded throughout the follow-up period, as well as in A1c and triglycerides, with
greatest improvement seen 2 years after surgery (51.8 ± 8.7 kg/m2 vs 42.3 ± 9.2 kg/m2, p < 0.05, 55.5 ± 19.1 mmol/mol vs 45.8 ±
13.7 mmol/mol, p < 0.05, and 2.2 ± 1.7 mmol/l vs 1.5 ± 0.6 mmol/l). Better outcomes were seen in younger patients, with lower
duration of diabetes before surgery, and lower pre-operative systolic blood pressure.
Conclusions Younger age, lower degree of obesity, and lower severity of comorbidities at the time of surgery can be important
predictors of successful weight loss, making this group of patients the ideal candidates for LAGB.
Keywords Laparoscopic adjustable gastric banding . Bariatric surgery . Obesity . T2DM . Hyperlipidemia . Hypertension .
Weight loss
Introduction
Laparoscopic adjustable gastric banding (LAGB) includes the
placement of a silicone ring around the stomach to create a
small upper gastric pouch at the bottom of the esophagus. This
procedure was introduced in the 1970s and remains safe, well
tolerated, and efficacious with a relative low risk of serious
complications. Another benefit to this procedure is the ability
to adjust the band enhancing its weight loss effect without
compromising safety. Furthermore, LAGB is a reversible
form of laparoscopic surgery making it an attractive option
for the majority of patients, although it is not promoted as a
temporary procedure due to the significant risk of weight re-
gain after removal [1, 2].
LAGB is ideally placed on the cardia of the stomach, just
below the esophagogastric junction. It is assumed that the
presence of a band in this position causes a meal to accumulate
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in the pouch of stomach proximal to it, before gradually being
released into the remainder of the gut. Thus, the band is
thought to work by restricting the volume of food ingested
to that able to be accommodated in the proximal pouch. This
small volume of food was thought to stretch the stomach and
cause early satiety. Gradual emptying of the proximal pouch
into the infra-band stomach is thought to be responsible for
prolonged inter-meal satiety [3]. More recently, it has been
hypothesized that LAGB mechanism of action includes the
induction of early and prolonged satiety; however, the
intraluminal events that lead to this are far more complex than
simple retention of food in the proximal pouch and merit fur-
ther evaluation beyond the scope of this manuscript [4].
Despite the above, clinical practice is moving away from
LAGB due to lower efficacy and high conversion to other
forms of surgery. Patients with dysphagia and/or regurgitation,
or poor weight loss response in the context of LAGB should
be evaluated for pseudoachalasia [5].
LAGB, nevertheless, remains a safe and effective treat-
ment, and it is crucial to identify specific patient characteris-
tics that predispose to good metabolic response to LAGB as
this can be invaluable in the optimization of current and de-
velopment of future tailored metabolic interventions to treat
obesity.
Materials and Methods
A retrospective analysis of 99 patients who underwent LAGB
over a period of 3 years was conducted. The study received
favorable ethical approval (GafREC ref: GF0366) by local
authorities.
Eligible for surgery were patients who met the National
Institute for Health and Care Excellence (NICE) clinical
guideline CG 189, with a body mass index (BMI) of ≥
35 kg/m2 and established obesity-related comorbidities in-
cluding type 2 diabetes mellitus (T2DM), obstructive sleep
apnea (OSA), hyperlipidemia, or other that could be improved
following weight loss, or ≥ 40 kg/m2 without any comorbidi-
ties, unable to achieve or maintain adequate weight loss fol-
lowing appropriate non-surgical interventions.
A standard LAGB procedure using pars flaccida technique
was performed in all cases by the same two experienced bar-
iatric surgeons. All patients were discharged on the first day
following surgery and band adjustments were performed at
scheduled intervals as per NICE guidance.
Clinical and biochemical assessments were performed at
baseline, 1, 2, and 5 years postoperatively. Weight and height
were measured in light clothing, and without shoes. Weight
loss after surgery was calculated using both total weight loss
(%TWL), and excess weight loss (%EWL). %TWL was ob-
tained applying the formula: (initial weight – post-op
weight) × 100/initial weight. %EWL was calculated by
dividing the number of kilograms lost by pre-operative excess
body weight (EBW), assuming a healthy BMI at 25 kg/m2.
Blood pressure was measured using Welch Allyn 7000-APM
blood pressure meter. The measurement was done twice, with
the patient seated for at least 10 min, and the average was
considered for analysis. Blood samples were obtained after
at least 8-h overnight fast to evaluate glucose and lipid metab-
olism. The change in different blood parameters (Δ) was
expressed in percentages out of the pre-operative values, fol-
lowing the formula: (Δ parameter) = (parameter value base-
line − parameter value postoperatively) × 100/parameter value
pre-op.
The presence of T2DM, hypertension, dyslipidemia, and
OSAwas assessed based on patients’medical records, clinical
examination, and blood test results. The improvement in
obesity-associated comorbidities was evaluated 1, 2, and
5 years postoperatively. The use of glucose lowering agents,
antihypertensive medication, and lipid lowering drugs was
recorded at each hospital visit.
Statistical analysis was performed using Statistical Package
for the Social Sciences Software (SPSS) version 20. Data was
reported as mean ± SD for continuous variables and in per-
centages for categorial variables. The comparisons between
parameters were carried out using parametric (paired sample
T test, independent sample T test) or non-parametric tests
(Chi-squared test), and correlations were performed using
Pearson analysis. A p value < 0.05 was considered statistically
significant.
Results
A total of 99 morbidly obese patients (17 men and 82 women)
underwent LAGB over a 3-year period. The patients had a
mean age at the time of surgery of 44.19 ± 10.94 years (range
22–71 years), and a mean BMI of 51.84 ± 8.77 kg/m2 (54.89
± 14.21 kg/m2 in men versus 51.22 ± 7.17 kg/m2 in women,
p = 0.013). Patients had a mean EBW of 74.74 ± 13.38 kg,
ranging between 25 and 122.8 kg. The prevalence of comor-
bidities was 42.4% for T2DM, 57.4% for hypertension, 28.7%
for dyslipidemia, and 26.3% were diagnosed with OSA.
Thirty-four of the patients included in the study had their
band removed at 5.5 ± 2.25 years after insertion, due to com-
plications. The main complication recorded was ineffective
weight loss, followed by slippage, erosion, and infection.
Data obtained after band removal was not included in our
analysis. There were no deaths attributable to the procedure.
Baseline, 1, 2, and 5 years data are presented in Table 1.
A decrease in medication use was recorded throughout the
follow-up period, and results are presented in Table 2.
Statistically significant was the decrease in the use of
antihyperglycemic and antihypertensive medication at 1 and
2 years postoperatively.
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In regard to weight loss, results of mean %EWL calculated
at 1, 2, and 5 years postoperatively were 29.91 ± 17.06%,
36.96 ± 25.65%, and 29.97 ± 25.68%, respectively, while
mean %TWL was 15.3 ± 8.51%, 18.57 ± 13.19%, and 15.63
± 13.57%. The effectiveness of the procedure was assessed
based either on %EWL (≥ 50%, or ≤ 25%), or %TWL (≥
20%) (Fig. 1).
In subgroup analysis, using gender or baseline BMI as
possible predictors of a good response to surgery, no statisti-
cally significant differences in the amount of %TWL or
%EWL were found. In contrast, younger patients lost more
weight through the follow-up period, with statistically signif-
icant results obtained 2 years after surgery (Fig. 2). The data is
presented in Tables 3 and 4.
Further exploration of the data available established a neg-
ative correlation between the duration of T2DM at surgery and
both 1 year%TWL (r = − 0.362, p = 0.028) and%EWL (r = −
0.393, p = 0.016), with poorer outcomes in patients with lon-
ger duration of T2DM before surgery. Another determinant of
%EWLwas the value of pre-operative systolic blood pressure,
a weak negative correlation being established between 2 years
%EWL and pre-op systolic blood pressure (SBP) (r = − 0.247,
p = 0.036). Two years after surgery, %EWL was higher in
patients without diabetes or hypertension, but not statistically
significant. Results are shown in Table 5.
When analyzing the improvement in metabolic profile 2
and 5 years postoperatively, better outcomes were noted in
patients with a lower BMI at baseline. Negative correlations
were established between initial BMI and % A1c and %
triglycerides (TG) at 2 and 5 years after surgery. Results are
presented in Table 6.
Discussion
With the continuous rise in the prevalence of obesity world-
wide, choosing the ideal treatment is both a challenge and a
necessity. All bariatric surgery procedures lead to substantial
weight loss and improvement in obesity-associated comorbid-
ities, although the rate of complications and long-term results
can be highly variable. The key to obtaining the best outcomes
is a personalized approach, which consists of identifying the
patients who could benefit the most from the currently avail-
able surgical options.
Even though the popularity of LAGB has been declining
rapidly in the past years due to high rates of ineffective weight
loss and frequent re-operations [3], the technical ease of the
procedure, the low early postoperative complications, and the
short length of hospitalization [3] could make it a feasible
option in a selected group of patients.
In the studied population, the mean initial BMI of 51.84 kg/
m2 was significantly higher compared with existing data.
O’Brien et al. report a mean baseline BMI of 43.2 kg/m2 when
analyzing a total of 8378 patients who underwent LAGB [4].
In addition, the prevalence of obesity-related comorbidities
was slightly higher than in other studies [6]. In a meta-
analysis which included 161,756 patients who underwent bar-
iatric surgery, the prevalence of T2DM was 26%,
Table 1 Sample general characteristics
Parameter Baseline 1 year post-op P value 2 years post-op P value 5 years post-op P value
BMI (kg/m2) 51.84 ± 8.77 43.99 ± 8.02 < 0.001 42.35 ± 9.26 < 0.001 43.40 ± 8.34 < 0.001
SBP (mmHg) 144.75 ± 17.63 143.32 ± 20.03 ns 140.58 ± 20.98 ns 140.55 ± 21.60 ns
DBP (mmHg) 78.61 ± 11.86 76.70 ± 11.16 ns 78.55 ± 13.37 ns 77.53 ± 10.92 ns
A1c (mmol/mol) 55.54 ± 19.11 45.71 ± 14.38 0.001 45.81 ± 13.73 0.002 49.75 ± 17.70 ns
Total Cho (mmol/l) 4.79 ± 0.96 4.94 ± 1.04 ns 4.93 ± 1.01 ns 4.94 ± 0.97 ns
HDL Cho (mmol/l) 1.33 ± 0.41 1.45 ± 0.42 0.037 1.52 ± 0.44 < 0.001 1.52 ± 0.45 0.003
LDL Cho (mmol/l) 2.53 ± 0.83 2.71 ± 0.99 ns 2.68 ± 0.98 ns 2.56 ± 0.97 ns
TG (mmol/l) 2.21 ± 1.76 1.69 ± 1.07 0.039 1.50 ± 0.66 0.006 1.85 ± 1.21 ns
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, HDL high-density lipoprotein, LDL low-density lipoprotein, TG
triglycerides
Table 2 Medication use
Medication use Baseline 1 year post-op P value 2 years post-op P value 5 years post-op P value
Glucose-lowering agents 36.8% 26.1% 0.025 27% 0.046 23.2% ns
Antihypertensive drugs 57.4% 53.8% 0.018 54.8% 0.004 52.9% ns
Lipid-lowering agents 28.7% 25.4% ns 24.3% ns 22.1% ns
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hypertension 47%, dyslipidemia 28%, and 25% for sleep ap-
nea [6], compared with our findings of 42.4%, 57.4%, 28.7%,
and 26.3% respectively.
In accordance with the existing literature [4], no deaths
attributable to the procedure were recorded, confirming the
safety of LAGB, which has the lowest mortality and compli-
cations rates compared with the other surgical interventions.
However, in contrast to other studies, higher reoperation rates
were found as the percentage of patients who had the band
removed due to complications was 34.34%, where the explan-
tation rates were 8.6% in a 20-year follow-up period of 3554
patients [4], 3.7% in 1791 obese patients followed up for
12 years [7]. Similar removal rates of 34.2% at 10 years and
46.7% at 15 years were reported by Carandina et al. when
analyzing data from 301 patients who underwent LAGB [8].
Arapis et al., in a study which included 897 patients, reported
a band failure of more than 70% at 15 years [9].
A statistically significant decrease in BMI from 51.82 to
43.99 kg/m2, 42.35 kg/m2, and 43.40 kg/m2was recorded 1, 2,
and 5 years postoperatively, with patients remaining morbidly
obese. In regard to the metabolic parameters, A1c dropped,
but with a mean value after surgery still in the prediabetic/
diabetic range (from 55.54 to 45.71 mmol/mol, 45.81 mmol/
mol, 49.75 mmol/mol), and high-density lipoprotein (HDL)
cholesterol slightly increased thought the follow-up period.
No change in total and low-density lipoprotein (LDL) choles-
terol was noted, and TG improved 2 years after surgery when
weight loss was maximal. These findings suggest that the
amount of weight loss was not sufficient to reach healthy
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Fig. 1 The effectiveness/
ineffectiveness of the procedure
was assessed using %EWL (≥
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Fig. 2 Younger patients lost more
weight through the follow-up pe-
riod, with statistically significant
results obtained 2 years after
surgery
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metabolic parameters. Others report better outcomes after
36 months in a study of 290 patients, with a significant de-
crease in blood pressure, glucose, and cholesterol levels [10].
However, the study population was younger (20–55 years
old), had lower initial BMI levels, and lower rates of comor-
bidities [10]. Similar findings were reported by Steffen et al. in
a 7-year prospective study on 388 patients undergoing LAGB
[11]. In a metanalysis by Li et al., rates of hypertension im-
provement were similar to those seen after laparoscopic sleeve
gastrectomy (61% versus 63%) [12]. In contrast, Aarts et al.,
after analyzing data from 201 patients followed up for
14 years, noticed that comorbidities returned or patients de-
veloped new ones, despite initially observed improvement
[13].
Mean %EWL at 1, 2, and 5 years postoperatively was
29.91%, 36.96%, and 29.97%, which is lower than in the
existing literature. In a recent paper on 3566 patients by
Furbetta et al., a mean of 49%, 53.6%, and 59.2% EWL was
recorded at 10, 15, and 20 years [14], demonstrating that
LAGB can be a highly effective surgical treatment of obesity
when a multidisciplinary approach is used. In the existing
studies, EWL% ranged between 27 and 65.7%, with a
follow-up duration from 10 to 16 years [4]. Mean %TWL of
15.3%, 18.57%, and 15.63% at 1, 2, and 5 years after surgery
was comparable with results obtained by O’Brien et al. [4] at
the same time points: 18.1%, 20.4%, and 19.5%. Maximum
weight loss was reached 2 years after surgery, using any of
%EWL or %TWL, result comparable with other studies
[4].Chang et al. [6] reported in their meta-analysis that youn-
ger age and pre-surgery BMI are positively correlated with the
amount of weight loss. Similar results were noted in our cur-
rent study. Patients aged < 45 years lost more weight, results
which were maintained through the follow-up period. Initial
BMI had an impact on improvement of comorbidities, not on
the amount of weight loss. Patients with lower pre-operative
weight had a better improvement in glucose and lipid profile
at 2 and 5 years after surgery, suggesting that baseline BMI
should be an important factor when choosing LAGB as an
obesity treatment. A systematic review looking at the out-
comes of LAGB in patients with BMI ≤ 35 kg/m2 reported
up to 71.9% EWL at 5 years, with partial or total resolution of
comorbidities [15]. Other studies reported better results in
male and older patients [16] or in those with higher initial
BMI [14, 16].
Table 3 %EWL in subgroup analysis
1 year P value 2 years P value 5 years P value
% EWL by gender
Men 33.83 ± 9.02 ns 36.47 ± 11.73 ns 27.00 ± 13.17 ns
Women 29.16 ± 18.15 37.06 ± 27.64 30.62 ± 27.71
% EWL by age
< 45 years 32.96 ± 20.10 ns 43.58 ± 29.98 0.011 34.81 ± 29.05 ns
≥ 45 years 26.78 ± 12.77 29.05 ± 16.42 25.13 ± 21.08
% EWL by initial BMI
< 50 kg/m2 31.22 ± 21.46 ns 35.82 ± 25.78 ns 27.48 ± 29.92 ns
≥ 50 kg/m2 29.09 ± 13.84 37.74 ± 25.81 31.28 ± 23.34
EWL excess weight loss, BMI body mass index
Table 4 %TWL in subgroup analysis
1 year P value 2 years P value 5 years P value
% TWL by gender
Men 17.37 ± 4.44 ns 18.62 ± 6.23 ns 14.28 ± 8.36 ns
Women 14.9 ± 9.05 18.56 ± 14.2 15.93 ± 14.5
% TWL by age
< 45 years 16.9 ± 9.81 ns 22.22 ± 15.6 0.006 18.31 ± 15.40 ns
≥ 45 years 13.65 ± 6.67 14.21 ± 7.74 12.95 ± 11.02
% TWL by initial BMI
< 50 kg/m2 14.34 ± 9.85 ns 15.72 ± 11.61 ns 12.03 ± 12.49 ns
≥ 50 kg/m2 15.9 ± 7.61 20.5 ± 13.95 17.54 ± 13.85
TWL total weight loss, BMI body mass index
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Limitations of this study include the retrospective design,
relatively small sample size, lack of quantifiable information
on the type and level of support these patients received from
the local bariatric multidisciplinary team, and lack of any mea-
sures of psychological wellbeing which may have impacted
on weight loss postoperatively.
In the presence of obesity-associated comorbidities, like
diabetes or hypertension, gastric band surgery proved to be
less effective, also confirmed by other studies [17].
Additionally, longer duration of diabetes at the time of surgery
and higher systolic blood pressure were negatively correlated
with the amount of weight loss. These findings indicate that
LAGB is more beneficial in patients without comorbidities at
the time of surgery, in line with the procedure’s restrictive
nature.
Conclusions
In order to improve the care of patients with obesity, careful
consideration should be given before choosing between the
available surgical procedures. LAGB has proven to be a safe,
reversible, and less invasive technique that can lead to effec-
tive weight loss and improvement of comorbidities. This study
found that younger age, lower degree of obesity, and lower
severity of comorbidities at the time of surgery may be impor-
tant predictors of successful weight loss, making this group of
patients the ideal candidates for LAGB.
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